Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages

Mycobacterium bovis BCG is attenuated strain derived from M. bovis. It has been known to prevent childhood pulmonaryand meningeal tuberculosis and to treat superficial bladder cancer as immunotherapy. Administration of BCG has beenrestricted to immune-deficient individuals since 2007 because of its combined complications. Which treated withantituberculosis drugs based on assumption is fully responsive to these drugs. BCG Connaught showed moresusceptibility to the activity of isoniazid, ethambutol, kanamycin, ofloxacin, streptomycin, amikacin and capreomycinthan BCG Pasteur growing in J774A.1 cells. While the activity of rifampicin and levofloxacin was the same between thetwo tested strains. The spectrum of intracellular drug action can be ordered based on a decreasing order of inhibitoryactivity, as following rifampin > isoniazid > ethambutol > streptomycin > kanamycin> amikacin> ofloxacin>capreomycin> levofloxacin against BCG Connaught. While rifampin > isoniazid > ethambutol > kanamycin =streptomycin > ofloxacin> amikacin> levofloxacin> capreomycin for BCG Pasteur. There is a very limited publicationsdescribe the activity of antituberculosis drugs against intracellular growing BCG strains